Table 2 Termination of p38 MAPK... | American Society of Hematology

Table 2

Termination of p38 MAPK inhibitor SB203580 treatment leads to EAE in immunized mice

Treatment	Incidence	DO^a	CDS^b	PS^c	DA^d	SI^e
D0-D30
Carrier	9/10	21.6 ± 3.6	16.9 ± 11.2	2.4 ± 1.0	9.1 ± 3.8	2.1 ± 0.6
SB203580	0/9	N/A	0	0	0	0
χ²	15.4
P	< .0001	< .0001	< .0001	< .0001	< .0001	< .0001
D31-D40
Carrier	8/10	N/A	19.8 ± 11.2	2.8 ± 0.7	10.0 ± 0	2.5 ± 0.4
SB203580	7/9	33.9 ± 2.0	13.1 ± 9.5	3.1 ± 1.1	7.1 ± 2.0	2.4 ± 0.7
χ²	0.01
P	.9		.2	.4	.001	.7
D41-D60
Carrier	9/10	N/A	42.0 ± 18.5	3.1 ± 0.8	20.0 ± 0	2.3 ± 0.6
SB203580	8/9	N/A	26.1 ± 10.9	2.8 ± 0.7	18.0 ± 4.3	1.5 ± 0.5
χ²	0.006
P	.9		.02	.34	.18	.005

Treatment	Incidence	DO^a	CDS^b	PS^c	DA^d	SI^e
D0-D30
Carrier	9/10	21.6 ± 3.6	16.9 ± 11.2	2.4 ± 1.0	9.1 ± 3.8	2.1 ± 0.6
SB203580	0/9	N/A	0	0	0	0
χ²	15.4
P	< .0001	< .0001	< .0001	< .0001	< .0001	< .0001
D31-D40
Carrier	8/10	N/A	19.8 ± 11.2	2.8 ± 0.7	10.0 ± 0	2.5 ± 0.4
SB203580	7/9	33.9 ± 2.0	13.1 ± 9.5	3.1 ± 1.1	7.1 ± 2.0	2.4 ± 0.7
χ²	0.01
P	.9		.2	.4	.001	.7
D41-D60
Carrier	9/10	N/A	42.0 ± 18.5	3.1 ± 0.8	20.0 ± 0	2.3 ± 0.6
SB203580	8/9	N/A	26.1 ± 10.9	2.8 ± 0.7	18.0 ± 4.3	1.5 ± 0.5
χ²	0.006
P	.9		.02	.34	.18	.005

Mice immunized for the induction of EAE were treated from day 0 to day 30 after immunization with either carrier or the p38 MAPK inhibitor SB203580 (5 mg/kg/d), stopped from day 31 to day 40, and resumed from day 41 to day 60. Animals were scored daily for clinical signs starting on day 10. Mean trait values ± SD are shown. The significance of the difference was calculated as in Table 1. P values ≤ .05 are considered significant.

EAE indicates experimental allergic encephalomyelitis; DO, day of onset; CDS, cumulative disease score; PS, peak score; DA, days affected; and SI, severity index.

View Large

This Feature Is Available To Subscribers Only